Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 69.4%

Neg 0% Neu 69.4% Pos 0%

Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.